Attached files

file filename
8-K - FORM 8-K - STERICYCLE INCbo8k0611.htm

EXHIBIT 99.1




FOR FURTHER INFORMATION CONTACT:

FOR IMMEDIATE RELEASE


Frank ten Brink  847-607-2012

 

Conference call to be held July 27, 2011 at 4:00 p.m. Central time – Dial 866-516-6872 at least 5 minutes before start time. If you are unable to participate on the call, a replay will be available through August 27th by dialing 855-859-2056, access code 79538389. To hear a live simulcast of the call over the internet on www.earnings.com, or to access an audio archive of the call, go to the Investors page on Stericycle’s website at www.stericycle.com.


STERICYCLE, INC. REPORTS RESULTS

FOR SECOND QUARTER 2011


Lake Forest, Illinois, July 27, 2011—Stericycle, Inc. (NASDAQ:SRCL), today reported financial results for the second quarter of 2011.


Revenues for the quarter ended June 30, 2011 were $410.4 million, up 18.0% from $347.7 million from the same quarter last year.  Acquisitions less than 12 months old contributed approximately $34.9 million to the growth in revenues.  The impact on revenues from foreign exchange in the quarter was $7.4 million favorable.  Gross profit was $186.7 million, up 15.6% from $161.5 million in the second quarter last year.  Gross profit as a percent of revenue was 45.5% compared with 46.5% in the second quarter of 2010.


Net income attributable to Stericycle for the second quarter of 2011 was $55.5 million or $0.63 per diluted share compared with $53.1 million or $0.61 per diluted share for the second quarter of 2010.  Net income attributable to Stericycle for the second quarter of 2011 reflected various non-operational items, which taken together, resulted in non-GAAP earnings per diluted share of $0.69 (see table below).  Our non-GAAP earnings per diluted share increased 11.9% from our non-GAAP earnings per share of $0.62 in the second quarter of 2010.  


FIRST SIX MONTHS’ RESULTS

For the six months ending June 30, 2011, revenues were $808.6 million, up 18.4% from $682.9 million in the same period last year. Revenues increased 17.0% compared with the prior period when adjusted for favorable foreign exchange impacts of $9.7 million.  Gross profit was $369.2 million, up 16.5% from $316.9 million in the same period last year.  Gross profit as a percent of revenue was 45.7% compared with 46.4% in 2010.  Earnings per diluted share increased to $1.27 from $1.17 per diluted share in the same period last year.  Non-GAAP earnings per diluted share, when adjusted for various non-operational items, increased from $1.18 to $1.37, or 15.7% (see table below):

 




Table to reconcile non-GAAP EPS to GAAP EPS

 

Three months ended June 30,

 

Six months ended June 30,

 

 

 

 

Change

 

 

 

 

Change

 

2011

2010

 

$

%

 

2011

2010

 

$

%

GAAP EPS

$0.63

$0.61

 

$0.02

3.1%

 

$1.27

$1.17

 

$0.10

8.5%

Acquisition expenses/Restructuring costs

0.05

0.01

 

 

 

 

0.09

0.02

 

 

 

Acceleration of Term Loan Fees

0.01

--

 

 

 

 

0.01

--

 

 

 

Non-GAAP EPS (adjusted)

$0.69

$0.62

 

$0.07

11.9%

 

$1.37

$1.18

 

$0.19

15.7%


* In accordance with U.S. generally accepted accounting principles (GAAP), reported earnings per share include the after-tax impact of the items identified in this table. For internal purposes, including the determination of management compensation, the Company excludes these items from results when evaluating operating performance. This table and the Company’s internal use of non-GAAP earnings per share are not intended to imply, and should not be interpreted as implying, that non-GAAP earnings per share is a better measure of performance than GAAP earnings per share.


Cash flow from operations was $119.7 million for the six months ended June 30, 2011.


For more information about Stericycle, please visit our website at www.stericycle.com


Safe Harbor Statement: Statements in this press release may contain forward-looking statements that involve risks and uncertainties, some of which are beyond our control (for example, general economic conditions). Our actual results could differ significantly from the results described in the forward-looking statements. Factors that could cause such differences include changes in governmental regulation of medical waste collection and treatment and increases in transportation and other operating costs, as well as the other factors described in our filings with the U.S. Securities and Exchange Commission. As a result, past financial performance should not be considered a reliable indicator of future performance, and investors should not use historical trends to anticipate future results or trends. We make no commitment to disclose any subsequent revisions to forward-looking statements.



STERICYCLE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS


In thousands, except share and per share data

 

 

June 30,

 

 

December 31,

 

 

2011

 

 

2010

 

 

(Unaudited)

 

 

(Audited)

 ASSETS

 

 

 

 

 

Current Assets:

 

 

 

 

 

     Cash and cash equivalents

$

38,199

 

$

77,053

     Short-term investments

 

19,063

 

 

18,471

     Accounts receivable, less allowance for doubtful

         accounts of $10,376 in 2011 and $10,845 in 2010

 

252,462

 

 

215,420

     Deferred income taxes

 

15,352

 

 

16,824

     Prepaid expenses

 

19,853

 

 

16,038

     Other current assets

 

26,718

 

 

24,882

         Total Current Assets

 

371,647

 

 

368,688

Property, Plant and Equipment, net

 

276,770

 

 

267,971

Other Assets:

 

 

 

 

 

     Goodwill

 

1,839,599

 

 

1,595,764

     Intangible assets, less accumulated amortization of

         $35,630 in 2011 and $28,394 in 2010

 

446,377

 

 

375,174

     Other

 

31,203

 

 

31,426

         Total Other Assets

 

2,317,179

 

 

2,002,364

Total Assets

$

2,965,596

 

$

2,639,023

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

Current liabilities:

 

 

 

 

 

     Current portion of long-term debt

$

67,879

 

$

88,899

     Accounts payable

 

58,346

 

 

54,777

     Accrued liabilities

 

114,221

 

 

134,711

     Deferred revenues

 

14,171

 

 

14,455

     Other current liabilities

 

13,718

 

 

15,647

         Total Current Liabilities

 

268,335

 

 

308,489

Long-term debt, net of current portion

 

1,165,395

 

 

1,014,222

Deferred income taxes

 

269,218

 

 

222,647

Other liabilities

 

11,616

 

 

13,315

Equity:

 

 

 

 

 

  

Common stock (par value $.01 per share, 120,000,000

     

shares authorized, 86,047,759 issued and outstanding

    

 in 2011 and 85,242,387 issued and outstanding in 2010)

 

860

 

 

852

  

Additional paid-in capital

 

94,365

 

 

46,945

 

Accumulated other comprehensive income

 

(287)

 

 

(16,869)

  

Retained earnings

 

1,128,713

 

 

1,017,497

         Total Stericycle, Inc.’s Equity

 

1,223,651

 

 

1,048,425

  

Noncontrolling interest

 

27,381

 

 

31,925

         Total Equity

 

1,251,032

 

 

1,080,350

     Total Liabilities and Equity

$

2,965,596

 

$

2,639,023





STERICYCLE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)


In thousands, except share and per share data

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

2011

 

2010

 

2011

 

2010

 

$

% of Rev

 

$

% of Rev

 

$

% of Rev

 

$

% of Rev

Revenues

410,441 

100.0

 

347,734 

100.0

 

808,567 

100.0

 

682,911 

100.0

Cost of revenues

223,708 

54.5

 

185,471 

53.3

 

439,342 

54.3

 

364,903 

53.3

Restructuring costs

(8) 

0.0

 

726 

0.2

 

54 

0.0

 

1,154 

0.2

Gross profit

186,741 

45.5

 

161,537 

46.5

 

369,171 

45.7

 

316,854 

46.4

Selling, general and administrative expenses

74,496 

18.2

 

65,091 

18.7

 

146,406 

18.1

 

129,113 

18.9

Amortization

3,546 

0.9

 

2,159 

0.6

 

6,893 

0.9

 

4,134 

0.6

Total SG&A expense and amortization

78,042 

19.0

 

67,250 

19.3

 

153,299 

19.0

 

133,247 

19.5

Income from operations before acquisition, integration, and other expenses

108,699 

26.5

 

94,287 

27.1

 

215,872 

26.7

 

183,607 

26.9

Acquisition expenses

5,261 

1.3

 

556 

0.2

 

9,059 

1.1

 

1,356 

0.2

Restructuring costs and plant closure expense

203 

0.0

 

837 

0.2

 

399 

0.0

 

1,076 

0.2

Litigation settlement

-- 

0.0

 

937 

0.3

 

-- 

0.0

 

937 

0.1

Gain on sale of assets

-- 

0.0

 

(2,955) 

-0.8

 

-- 

0.0

 

(2,955) 

-0.4

Integration expenses

1,287 

0.3

 

1,314 

0.4

 

2,053 

0.3

 

2,463 

0.4

Income from operations

101,948 

24.8

 

93,598 

26.9

 

204,361 

25.3

 

180,730 

26.5

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

Interest income

63 

0.0

 

32 

0.0

 

247 

0.0

 

112 

0.0

Interest expense

(13,007)

-3.2

 

(8,870)

-2.6

 

(24,379)

-3.0

 

(17,833)

-2.6

Other expense, net

(819)

-0.2

 

(892)

-0.3

 

(1,082)

-0.1

 

(1,895)

-0.3

Total other expense

(13,763)

-3.4

 

(9,730)

-2.8

 

(25,214)

-3.1

 

(19,616)

-2.9

Income before income taxes

88,185 

21.5

 

83,868 

24.1

 

179,147 

22.2

 

161,114 

23.6

Income tax expense

32,295 

7.9

 

30,102 

8.7

 

66,671 

8.2

 

58,714 

8.6

Net income

55,890 

13.6

 

53,766 

15.5

 

112,476 

13.9

 

102,400 

15.0

Net income attributable to noncontrolling interests

348 

0.1

 

672 

0.2

 

1,260 

0.2

 

1,187 

0.2

Net income attributable to Stericycle, Inc.

55,542 

13.5

 

53,094 

15.3

 

111,216 

13.8

 

101,213 

14.8

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share-diluted

0.63

 

 

0.61

 

 

1.27

 

 

1.17

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding-diluted

87,935,310

 

 

86,694,239

 

 

87,738,638

 

 

86,646,109

 



STERICYCLE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)


In thousands

 

 

Six Months Ended June 30,

 

 

2011

 

 

2010

OPERATING ACTIVITIES:

 

 

 

 

 

Net income

$

112,476

 

$

102,400

Adjustments to reconcile net income to net cash provided

   by operating activities:

 

 

 

 

 

     Gain on sale of assets

 

--

 

 

(2,955)

     Change in fair value of contingent consideration

 

(2,140)

 

 

--

     Accelerated amortization of term loan financing fees

 

1,241

 

 

--

     Stock compensation expense

 

7,718

 

 

7,741

     Excess tax benefit of stock options exercised

 

(14,549)

 

 

(13,430)

     Depreciation

 

24,161

 

 

20,872

     Amortization

 

6,893

 

 

4,134

     Deferred income taxes

 

18,734

 

 

12,110

Changes in operating assets and liabilities, net of effect of

   acquisitions and divestitures:

 

 

 

 

 

     Accounts receivable

 

(22,584)

 

 

(11,688)

     Accounts payable

 

(5,531)

 

 

(5,436)

     Accrued liabilities

 

(4,987)

 

 

9,042

     Deferred revenues

 

(566)

 

 

1,826

     Other assets and liabilities

 

(1,172)

 

 

4,689

Net cash provided by operating activities

 

119,694

 

 

129,305

 

 

 

 

 

 

INVESTING ACTIVITIES:

 

 

 

 

 

     Payments for acquisitions and international investments,

         net of cash acquired

 

(280,823)

 

 

(67,826)

     (Purchase of) / proceeds from short-term investments

 

(403)

 

 

(911)

     Proceeds from sale of property and equipment

 

389

 

 

8,000

     Capital expenditures

 

(23,652)

 

 

(25,017)

Net cash used in investing activities

 

(304,489)

 

 

(85,754)

 

 

 

 

 

 

FINANCING ACTIVITIES:

 

 

 

 

 

     Repayment of long-term debt

 

(5,260)

 

 

(44,126)

     Net borrowings/ (repayments) on senior credit facility

 

126,600

 

 

(18,249)

     Payments of deferred consideration

 

(12,834)

 

 

--

     Payments on capital lease obligations

 

(1,456)

 

 

(1,829)

     Purchase/ cancellation of treasury stock

 

(4,302)

 

 

(24,260)

     Proceeds from other issuance of common stock

 

27,069

 

 

25,334

     Excess tax benefit of stock options exercised

 

14,549

 

 

13,430

Net cash provided by/ (used in) financing activities

 

144,366

 

 

(49,700)

Effect of exchange rate changes on cash

 

1,575

 

 

(1,367)

Net decrease in cash and cash equivalents

 

(38,854)

 

 

(7,516)

Cash and cash equivalents at beginning of period

 

77,053

 

 

15,767

Cash and cash equivalents at end of period

$

38,199

 

$

8,251

 

 

 

 

 

 

NON-CASH ACTIVITIES:

 

 

 

 

 

Net issuance of notes payable for certain acquisitions

$

4,922

 

$

31,042